enGene Inc. (ENGN)
| Bid | 3.65 |
| Market Cap | 194.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.25M |
| EPS (ttm) | -1.63 |
| PE Ratio (ttm) | -2.33 |
| Forward PE | -1.67 |
| Analyst | Buy |
| Ask | 3.9 |
| Volume | 26,296 |
| Avg. Volume (20D) | 83,482 |
| Open | 3.70 |
| Previous Close | 3.68 |
| Day's Range | 3.64 - 3.94 |
| 52-Week Range | 2.65 - 11.00 |
| Beta | -0.41 |
About ENGN
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement...
2 months ago · seekingalpha.com
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, E...
2 months ago · businesswire.com
enGene Reports Second Quarter 2025 Financial Results and Provides Business UpdateBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...
